Stem cell

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

Retrieved on: 
Tuesday, April 2, 2024
Health, B cell, Longevity, Biotechnology, Patient, Research, Stem cell, Safety, Peptide, Medicine

As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.

Key Points: 
  • As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.
  • They wowed delegates with their pioneering research and clinical innovations in bioregenerative medicine, putting EWBG at the forefront of the industry.
  • Mike Chan, known for his innovative pioneering work in stem cells and bioregenerative medicine, presented his most recent research discoveries, promising to transform how age-related illnesses are treated.
  • The presence of the 2 prominent speakers at AMWC 2024 demonstrates EWBG's dedication to advancing medical sciences for the benefit of humanity.

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

Retrieved on: 
Tuesday, April 2, 2024
Health, B cell, Longevity, Biotechnology, Patient, Research, Stem cell, Safety, Peptide, Medicine

As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.

Key Points: 
  • As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.
  • They wowed delegates with their pioneering research and clinical innovations in bioregenerative medicine, putting EWBG at the forefront of the industry.
  • Mike Chan, known for his innovative pioneering work in stem cells and bioregenerative medicine, presented his most recent research discoveries, promising to transform how age-related illnesses are treated.
  • The presence of the 2 prominent speakers at AMWC 2024 demonstrates EWBG's dedication to advancing medical sciences for the benefit of humanity.

Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats

Retrieved on: 
Monday, March 25, 2024
Research, ESC, Bioreactor, B cell, Regeneration, Neurology, Rat, Cell, Osteogenesis imperfecta, Assistant, Cardiology, Critical Care Medicine (journal), Patient, American Journal, DNA, Pharmacist, Manuscript, Cancer, University, Hope, Doctor of Philosophy, Lung transplantation, MD, Biostatistics, Respiratory failure, Cas9, CRISPR, Stem cell, Premature, Research institute, College of Engineering (KNUST), Medicine, Nursing, Animal

PHOENIX, March 25, 2024 /PRNewswire/ -- Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Key Points: 
  • The critical differentiating factor with this study is researchers incorporated CRISPR-Cas9, a unique genome editing technology that allows researchers to change genomes by altering sections of the DNA sequence.
  • Modifications of rat embryos by CRISPR-Cas9 allowed the formation of lung tissues consisting of almost all mouse lung cells.
  • This is one of many recent accolades for the Phoenix Children's Research Institute.
  • The Phoenix Children's Research Institute at the University of Arizona College of Medicine –Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the University of Arizona College of Medicine – Phoenix.

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .

L-Nutra Health® Pioneers New, Innovative Therapeutic Healthcare Model with Official Diabetes Patent

Retrieved on: 
Tuesday, March 19, 2024
Stem cell, Glucose, Facial muscles, Longevity, Regeneration, FMD, Health, Diabetes, Patient, Harvard University, Weight loss, Hope, Joslin Diabetes Center, Insulin resistance, Patent, Physician, Ageing, Pharmaceutical industry

With this historic achievement in nutrition-led healthcare, L-Nutra Health® solidifies its position as the authoritative leader in science-backed nutrition technology.

Key Points: 
  • With this historic achievement in nutrition-led healthcare, L-Nutra Health® solidifies its position as the authoritative leader in science-backed nutrition technology.
  • The comprehensive program includes supervision by lifestyle medicine physicians and personalized support from dietitians uniquely trained in longevity and diabetes.
  • Through nutrition, L-Nutra Health® is redefining the landscape of type 2 diabetes management and the speed of regression.
  • "This patent stands as a testament to our steadfast commitment to providing pioneering solutions that define a new therapeutic category, positioning L-Nutra Health® at the forefront of healthcare."

LifeSpan Vision Ventures Invests in SENISCA

Retrieved on: 
Tuesday, March 19, 2024
University, Stem cell, Therapy, RNA splicing, RNA, Longevity, Investment, Notifiable disease, Cell, Science, Vaccine

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.

Key Points: 
  • NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.
  • Senescent cells behave differently to young, healthy cells in several ways, such as ceasing growth and secreting pro-inflammatory chemicals.
  • Harry Robb, Analyst, LifeSpan Vision Ventures, commented: "We are delighted to join SENISCA as new investors in this financing round.
  • Dr Sarah Cole, CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA.

LifeSpan Vision Ventures Invests in SENISCA

Retrieved on: 
Tuesday, March 19, 2024
University, Stem cell, Therapy, RNA splicing, RNA, Longevity, Investment, Notifiable disease, Cell, Science, Vaccine

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.

Key Points: 
  • NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.
  • Senescent cells behave differently to young, healthy cells in several ways, such as ceasing growth and secreting pro-inflammatory chemicals.
  • Harry Robb, Analyst, LifeSpan Vision Ventures, commented: "We are delighted to join SENISCA as new investors in this financing round.
  • Dr Sarah Cole, CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA.

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Retrieved on: 
Thursday, March 14, 2024
Stem cell, Patient, Research, Factorization of polynomials, Science Immunology, POC, Publication, Asgard, Therapy, Immune system, Recreation, Investment, Pharmaceutical industry

The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Key Points: 
  • The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
  • AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprograms tumor cells into antigen-presenting dendritic cells, ultimately leading to a personalized anti-tumor immune response.
  • João Ribas, Principal, Novo Holdings, Seed Investments, said: "We're thrilled to welcome new investors JJDC and RV Invest to Asgard Therapeutics.
  • This marks a significant milestone for Asgard's novel concept of direct in vivo cellular reprogramming in oncology.

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Retrieved on: 
Thursday, March 14, 2024
Stem cell, Patient, Research, Factorization of polynomials, Science Immunology, POC, Publication, Asgard, Therapy, Immune system, Recreation, Investment, Pharmaceutical industry

The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Key Points: 
  • The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
  • AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprograms tumor cells into antigen-presenting dendritic cells, ultimately leading to a personalized anti-tumor immune response.
  • João Ribas, Principal, Novo Holdings, Seed Investments, said: "We're thrilled to welcome new investors JJDC and RV Invest to Asgard Therapeutics.
  • This marks a significant milestone for Asgard's novel concept of direct in vivo cellular reprogramming in oncology.

Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Stem cell, Dicarboxylic acid, Dental implant, Health, Dentistry, Gene, University, Chair, UBC, Erosion, Sepsis, Prevalence, Multiple organ dysfunction syndrome, Risk, COVID-19, Inflammation, Patient, Artificial intelligence, Bacteria, DSM-IV codes, AI, Death, Biofilm, Staphylococcus aureus, LASSO, Infection, Pathology, Therapy, ICU, FDA, The Lancet, Peptide

These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.

Key Points: 
  • These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.
  • AI was also used to simplify the extreme complexity7 of sepsis, which has limited treatments to date.
  • While others are trying to figure out how AI can be best used, we are already using it with amazing success in diagnostics and therapeutics.
  • Asep Inc. is dedicated to leveraging AI's power to improve human health," said Dr. Evan Haney, Chief Scientific Officer of Asep.